DYADIC startet

  16.03.12      1,00      1,15§0,99 1,15 $ 41.036 47.191
  15.03.12      1,02      1,14§1,00 1,14 $ 22.183 25.289
  14.03.12      1,20      1,20§0,99 1,15 $ 23.549 27.081
  13.03.12      0,99      1,20§0,97 1,20 $ 44.630 54 T
  12.03.12      1,02      1,20§1,00 1,20 $ 16.300 19.560
  09.03.12      0,97      1,23§0,97 1,00 $ 10.280 10.280
  08.03.12      1,04      1,22§0,90 1,22 $ 41.702 51 T
  07.03.12      1,08      1,14§1,08 1,14 $ 9.958 11.352
  06.03.12      1,15      1,15§1,15 1,15 $ 6.740 7.751
  05.03.12      1,07      1,22§1,07 1,19 $ 11.860 14.113
  02.03.12      1,14      1,20§1,14 1,19 $ 12.200 14.518
  01.03.12      1,20      1,27§1,08 1,20 $ 11.697 14.036

  14.05.12      0,95      1,08§0,95 1,08 $ 7.600 7.817
  11.05.12      0,95      1,11§0,95 1,09 $ 7.300 7.776
  10.05.12      1,07      1,14§0,93 0,95 $ 107.391 105 T
  09.05.12      1,05      1,15§1,05 1,11 $ 16.500 18.563
  08.05.12      1,10      1,25§1,00 1,20 $ 14.700 15.617
  07.05.12      1,03      1,29§1,00 1,16 $ 18.698 19.947
  04.05.12      1,10      1,29§1,05 1,12 $ 24.200 26.416
  03.05.12      1,26      1,27§1,11 1,24 $ 9.475 11.745
  02.05.12      1,27      1,34§1,27 1,29 $ 6.649 7.223
  01.05.12      1,16      1,48§1,12 1,27 $ 277.180 356 T
  30.04.12      1,07      1,15§1,05 1,15 $ 6.600 7.093

For EU-Funded Research Consortium

15:20 02.07.12

PR Newswire

JUPITER, Fla. and WAGENINGEN, The Netherlands, July 2, 2012

JUPITER, Fla. and WAGENINGEN, The Netherlands, July 2, 2012 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the industrial enzyme, bioenergy, and biopharmaceutical industries, announced today that its research and development center in the Netherlands is a member of the Bio-Mimetic Project, a new multidisciplinary research consortium that has been awarded a EUR 3.5 million grant from the European Community's Seventh Framework Programme (FP7) of the European Community for Research, Technological Development and Demonstration Activities. The European consortium is commencing a three year research project entitled, "New Bio-Inspired Processes and Products from Renewable Feedstock" which will employ environmentally-friendly technologies to convert the renewable agricultural waste stream, lignin, into high value sustainable commercial products such as adhesives, detergents and cosmetics.

(Logo: photos.prnewswire.com/prnh/20110621/CL06708LOGO)

Wim van der Wilden, the General Manager of Dyadic Netherlands, stated, "We are very pleased to have the opportunity to work with such fine organizations on a highly innovative project where we can demonstrate the efficacy and productivity of our C1 technology to use green chemistry to find commercial applications for lignin. If successful, this project will be a promising step forward in using this renewable waste stream to replace traditional toxic, expensive and high energy consuming processes."

As part of the Bio-Mimetic Project, Dyadic Netherlands will receive approximately EUR 400,000 to develop enzymes using Dyadic's patented and proprietary C1 platform technology to degrade and modify lignin so that it can be used to create these high value commercial products.

Procter & Gamble Technical Centres Limited (P&G UK) will serve as the coordinator of the Bio-Mimetic Project Consortium which, in addition to Dyadic Netherlands, consists of the following participants:

   Fraunhofer Institute IFAM (Germany)
   The University of Rome Tor Vergata (Italy)
   MAVI Sud s.r.l. (Italy)
   Gulgi B.V. (The Netherlands)
   Compagnie Industrielle de la Matiere Vegetale (CIMV)(France)
   Procter & Gamble Eurocor N.V. (P&G Brussels Innovation Centre)(Belgium)
   CiaoTech s.r.l (Italy)
   The University of Manchester (United Kingdom)

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and others proteins for the bioenergy, industrial enzyme and biopharmaceutical industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Dyadic Netherlands is a wholly owned subsidiary of Dyadic based in Wageningen, The Netherlands that conducts research and development activities for the benefit of Dyadic, its collaborators and customers. Please visit Dyadic Netherlands' website at www.dyadic.nl.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.
Quelle: PR Newswire